Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING NA

PARTNER 3 Trial - Mitral Valve in Valve

NCT03193801 · View on ClinicalTrials.gov ↗

Study Summary

To assess the safety and effectiveness of the SAPIEN 3 transcatheter heart valve in patients with a failing mitral bioprosthetic valve.

Interventions

  • DEVICE Edwards SAPIEN 3 transcatheter valve, Model 9600TFX

Study Locations (12)

Illinois

  • Northwestern University — Chicago
  • Northshore University Health System Research Institution — Evanston

São Paulo

  • Instituto do Coração da Universidade de São Paulo — Cerqueira César
  • Instituto Dante Pazzanese de Cardiologia — Vila Mariana

Georgia

  • Emory University — Atlanta

Massachusetts

  • Brigham and Women's Hospital — Boston

Minnesota

  • Mayo Clinic — Rochester

Missouri

  • Barnes-Jewish Hospital/ Washington University — St Louis

New York

  • NYU Lagone Medical Center — New York

Oregon

  • Providence Heart & Vascular Institution — Portland

Trial Details

FieldValue
Enrollment Target 53 participants
Start Date 2018-02-01
Est. Completion 2031-08
Phase NA

Sponsor

Edwards Lifesciences

34 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03193801

The ClinicalTrials.gov registry entry for NCT03193801 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Edwards Lifesciences, which has 34 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 4 conditions, with Heart Failure appearing as the primary indexed condition, and to 1 intervention — of which Edwards SAPIEN 3 transcatheter valve, Model 9600TFX is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT03193801 reports 12 study locations spanning 10 distinct geographic areas — top geographies include Illinois, São Paulo, Georgia. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT03193801 about?

NCT03193801 is a clinical study titled "PARTNER 3 Trial - Mitral Valve in Valve". To assess the safety and effectiveness of the SAPIEN 3 transcatheter heart valve in patients with a failing mitral bioprosthetic valve.

What is the current status of trial NCT03193801?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 53 participants. The study started on 2018-02-01. Estimated completion is 2031-08.

What conditions does trial NCT03193801 study?

This clinical trial studies the following conditions: Heart Failure, Mitral Valve Insufficiency, Mitral Valve Regurgitation, Mitral Valve Disease. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT03193801?

The interventions under investigation include: Edwards SAPIEN 3 transcatheter valve, Model 9600TFX (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT03193801?

This trial is sponsored by Edwards Lifesciences, which has 34 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT03193801 being conducted?

This trial has 12 study locations across Georgia, Illinois, Massachusetts, Minnesota, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial